Literature DB >> 7253364

Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhea of colitis.

J G Bartlett.   

Abstract

Records were reviewed for 329 patients who had antibiotic-associated diarrhea or colitis with stools showing a cytopathic toxin which is neutralized by Clostridium sordellii antitoxin. Previous studies indicate that the detection of this toxin implicate Clostridium difficile as the responsible pathogen. A spectrum of anatomical results in the colonic mucosa were found ranging from pseudomembranous colitis in 136 patients to an entirely normal endoscopic condition in 36 patients. The most frequently implicated agents were ampicillin, clindamycin, and cephalosporins. Collectively, these drugs accounted for approximately 80% of cases in which a single antimicrobial had been administered prior to the onset of symptoms. Analysis of data obtained in sequential time intervals showed a decline in the relative frequency of cases with use of clindamycin accompanied by an increase with use of cephalosporins. Less frequent drugs which were implicated in 3-8% of cases were, in rank order, penicillins other than ampicillin, erythromycin, sulfamethoxazole-trimethoprim and sulfasalazine. Tetracycline was the exclusive agent given to only three patients and there were no patients in whom chloramphenicol could be clearly implicated.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7253364

Source DB:  PubMed          Journal:  Johns Hopkins Med J        ISSN: 0021-7263


  25 in total

1.  The macrolide-lincosamide-streptogramin B resistance determinant from Clostridium difficile 630 contains two erm(B) genes.

Authors:  K A Farrow; D Lyras; J I Rood
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Effects of antibiotics and other drugs on toxin production in Clostridium difficile in vitro and in vivo.

Authors:  M C Barc; C Depitre; G Corthier; A Collignon; W J Su; P Bourlioux
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

3.  Clostridium difficile infection of the gut.

Authors:  A P Dodson; S P Borriello
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

4.  Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection.

Authors:  J A Kink; J A Williams
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

5.  Clostridium difficile in an oncology unit.

Authors:  A L Brunetto; A D Pearson; A W Craft; S J Pedler
Journal:  Arch Dis Child       Date:  1988-08       Impact factor: 3.791

6.  Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Authors:  Pauline M Anton; Michael O'Brien; Efi Kokkotou; Barry Eisenstein; Arthur Michaelis; David Rothstein; Sophia Paraschos; Ciáran P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Clostridium difficile in urology.

Authors:  M Hossain; T J Crook; S R Keoghane
Journal:  Ann R Coll Surg Engl       Date:  2008-01       Impact factor: 1.891

Review 8.  The clinical significance of antibiotic-associated pseudomembranous colitis in the 1990s.

Authors:  M Andréjak; J L Schmit; A Tondriaux
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

9.  In vitro susceptibility of Clostridium difficile to new beta-lactam and quinolone antibiotics.

Authors:  A W Chow; N Cheng; K H Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

Review 10.  Clostridium difficile: clinical disease and diagnosis.

Authors:  F C Knoop; M Owens; I C Crocker
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.